Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Yoshimasa, Miyagawa"'
Autor:
Keiko Inakami, Noriko Fujita, Chikage Iguchi, Yukie Enomoto, Junya Minohata, Atsushi Sata, Yoshimasa Miyagawa, Tetsu Yanagisawa, Tomokazu Saitoh, Takashi Nomura, Yuka Sawai, Keiko Takahara, Tsutomu Kasugai, Eiichi Shiba
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-6 (2024)
Abstract Background Pembrolizumab (PEM), an immune checkpoint inhibitor (ICI), is often used for triple-negative breast cancer, but can also be used to treat solid tumors that exhibit high microsatellite instability (MSI-High). However, patients with
Externí odkaz:
https://doaj.org/article/20aff28844e8466f92c48eee2fbc960b
Autor:
Kazuhiro Araki, Yoshinori Ito, Ippei Fukada, Kokoro Kobayashi, Yoshimasa Miyagawa, Michiko Imamura, Ayako Kira, Yuichi Takatsuka, Chiyomi Egawa, Hirofumi Suwa, Shinji Ohno, Yasuo Miyoshi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstracts Background Although peripheral blood-based parameters (PBBPs) are reported as prognostic indicators in patients with breast cancers, their utility has not been studied in human epidermal growth factor receptor 2 (HER2)-positive advanced bre
Externí odkaz:
https://doaj.org/article/29f5a70f15404664a88f5d345caa82d3
Autor:
Michiko Imamura, Takashi Morimoto, Takashi Nomura, Shintaro Michishita, Arisa Nishimukai, Tomoko Higuchi, Yukie Fujimoto, Yoshimasa Miyagawa, Ayako Kira, Keiko Murase, Kazuhiro Araki, Yuichi Takatsuka, Koshi Oh, Yoshikazu Masai, Kouhei Akazawa, Yasuo Miyoshi
Publikováno v:
World Journal of Surgical Oncology, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background Although the prognosis for operable breast cancers is reportedly worse if serum carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels are above normal, the usefulness of this prognosis is limited due to the low se
Externí odkaz:
https://doaj.org/article/5a6e30eea34e484e8a64a217e128c415
Autor:
Tomoko Higuchi, Reiko Fukui, Hiromi Ozawa, Michiko Imamura, Yoshimasa Miyagawa, Atsushi Sata, Natsuko Inoue, Ayako Bun, Yasuo Miyoshi, Yukie Fujimoto
Publikováno v:
Cancer Research. 81:PS4-20
(Background)Eribulin, a non-taxane inhibitor of microtubule dynamics, is a unique chemotherapy agent for locally advanced or metastatic breast cancer (MBC). The treatment has been demonstrated to extend overall survival (OS) without extending progres
Autor:
Yasuo Miyoshi, Yoshimasa Miyagawa, Chiyomi Egawa, Atsushi Sata, Takehiro Yanagawa, Takashi Morimoto, Hiromi Ozawa, Ayako Bun, Kaori Takamoto, Yukie Fujimoto, Arisa Nishimukai, Tomoko Higuchi, Reiko Fukui, Jyunichi Inatome, Ayako Yanai, Michiko Imamura
Publikováno v:
Cancer Research. 80:P3-08
Background Vascular endothelial growth factor (VEGF) is a key player in angiogenesis, and bevacizumab, a humanized monoclonal antibody against VEGF-A, is already utilized in daily clinical practice coupled with chemotherapy for locally advanced and m
Autor:
Reiko Fukui, Tomoko Higuchi, Yukie Fujimoto, Atsushi Sata, Ayako Bun, Hiromi Ozawa, Yoshimasa Miyagawa, Michiko Imamura, Kazuhiro Kitajima, Yasuo Miyoshi
Publikováno v:
Cancer Research. 80:P3-08
Background Endocrine therapy is an essential treatment choice for patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced and metastatic breast cancers. Although patients with non-vi
Autor:
Noriko Fujita, Koichi Fujita, Seung Jin Kim, Chikage Iguchi, Takashi Nomura, Toyokazu Aono, Tetsu Yanagisawa, Yukie Enomoto, Keiko Inakami, Yoshimasa Miyagawa, Riki Tomoike, Tsutomu Kasugai, Eiichi Shiba
Publikováno v:
Oncology. 100(5)
Background: De-escalation therapy omitting anthracycline has been generally adopted for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC)
Autor:
Ai Yamaguchi, Michiko Imamura, Yuki Okada, Tomoe Taji, Arisa Nishimukai, Tomoko Higuchi, Ayako Yanai, Takashi Morimoto, Takehiro Yanagawa, Ayako Bun, Hirofumi Suwa, Yuichiro Kikawa, Yasuo Miyoshi, Yoshimasa Miyagawa, Atsushi Sata, Hiromi Ozawa, Chiyomi Egawa, Kaori Takamoto, Yukie Fujimoto, Reiko Fukui, Junichi Inatome
Publikováno v:
Oncotarget
The effect of bevacizumab plus paclitaxel therapy on progression-free survival (PFS) is prominent; however, no overall survival (OS) benefit has been demonstrated. Our aim was to study the predictive efficacy of peripheral immune-related parameters,
Autor:
Michiko Imamura, Reiko Fukui, Yukie Fujimoto, Yoshimasa Miyagawa, Tomoko Higuchi, Hiromi Ozawa, Yasuo Miyoshi, Ayako Bun, Atsushi Sata
Publikováno v:
Anticancer Research. 39:5653-5662
Background/aim Factors influencing fulvestrant efficacy may be useful in selecting the optimal treatment regimen for postmenopausal Japanese women with metastatic/recurrent HR-positive, HER2-negative breast cancer. Patients and methods We retrospecti
Autor:
Yoshimasa Miyagawa, Ayako Bun, Yasuo Miyoshi, Reiko Fukui, Kazuhiro Kitajima, Hiromi Ozawa, Michiko Imamura, Yukie Fujimoto, Koichiro Yamakado, Tomoko Higuchi
Publikováno v:
Annals of Surgical Oncology. 26:2175-2183
The usefulness of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography for evaluating the treatment efficacy of breast cancers is well-established; however, the predictive values of parameters such as metabolic tumor volume (MTV) a